Thursday, April 27, 2017 10:01:42 PM
1) All the literature says that they are determining the dosage on large animals. After that,it says there will be another "pivotal trial" that will lead to fast commercial marketization. Maybe the final trial is a fast track that evaluates safety?
OR
2) If they are treating ARS, the safety concerns may take a back seat to the fact that a population will have a high death rate either way. Safety wouldn't matter if a person is probably dead anyway. I'd guess there is an exemption based on compassionate use.
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM